shRNA-mediated decreases in c-Met levels affect the differentiation potential of human mesenchymal stem cells and reduce their capacity for tissue repair by Rosová, Ivana et al.




shRNA-mediated decreases in c-Met levels affect
the differentiation potential of human
mesenchymal stem cells and reduce their capacity
for tissue repair
Ivana Rosová
Washington University School of Medicine
Daniel Link
Washington University School of Medicine
Jan A. Nolta
University of California, Davis
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Rosová, Ivana; Link, Daniel; and Nolta, Jan A., ,"shRNA-mediated decreases in c-Met levels affect the differentiation potential of
human mesenchymal stem cells and reduce their capacity for tissue repair." Tissue Engineering Part A.16,8. 2627-2639. (2010).
http://digitalcommons.wustl.edu/open_access_pubs/4649
shRNA-Mediated Decreases in c-Met Levels
Affect the Differentiation Potential of Human
Mesenchymal Stem Cells and Reduce
Their Capacity for Tissue Repair
Ivana Rosova´, Ph.D.,1 Daniel Link, M.D.,1 and Jan A. Nolta, Ph.D.2
Mesenchymal stem cells/marrow stromal cells (MSC) are adult multipotent cells that can augment tissue repair.
We previously demonstrated that culturing MSC in hypoxic conditions causes upregulation of the hepatocyte
growth factor (HGF) receptor c-Met, allowing them to respond more robustly to HGF. MSC preconditioned in
hypoxic environments contributed to restoration of blood flow after an ischemic injury more rapidly than MSC
cultured in normoxic conditions. We now investigated the specific role of HGF/c-Met signaling in MSC function.
An shRNA-mediated knockdown (KD) of c-Met in MSC did not alter their phenotypic profile, proliferation, or
viability in vitro. However, we determined that while HGF/c-Met signaling does not play a role in the adipogenic
differentiation of the cells, the disruption of this signaling pathway inhibited the ability ofMSC to differentiate into
the osteogenic and chondrogenic lineages. We next assessed the impact of c-Met KD on humanMSC function in a
xenogeneic hindlimb ischemia injury model. A 70% KD of c-Met in MSC resulted in a significant decrease in their
capacity to regenerate blood flow to the ischemic limb, as compared to the MSC transduced with control shRNA.
MSC with only a 60% KD of c-Met exhibited an intermediate capacity to restore blood flow, suggesting that MSC
function is sensitive to the dosage of c-Met signaling. The current study highlights the significance of HGF/c-Met
signaling in the capacity of MSC to restore blood flow after an ischemic injury and in their ability to differentiate
into the osteogenic and chondrogenic lineages.
Introduction
Mesenchymal stem cells/marrow stromal cells (MSC)are adult multipotent cells with defined characteristics1
that are most commonly isolated from the bone marrow, but
are also present in other adult tissues. MSC differentiate into
multiple tissue-specific cells in vitro and in vivo, including
chondrogenic, osteogenic, adipogenic, neural, and cardiac
lineages.2–4 An intriguing and widely explored area of re-
search has been focused on using MSC as a cell therapeutic
agent, promoting repair after tissue damage. In several injury
models such as cardiac infarction and hindlimb ischemia,
MSC have been shown to improve tissue regeneration and
blood flow recovery.5,6 Although the exact mechanism of how
MSC mediate tissue repair is still unknown, the current evi-
dence suggests that their ability to secrete trophic factors is
important for their regenerative properties.7
Hepatocyte growth factor (HGF) is a pleiotropic cytokine
that has been described to be activated upon tissue injury
such as cardiac infarction, liver damage, and skeletal muscle
injury.5,8,9 In the adult tissues, HGF serves as a potentmitogen
and organotrophic factor, promoting tissue regeneration. It is
also an angiogenic factor stimulating endothelial cell prolif-
eration.10,11 Additionally, HGF stimulates cell scattering and
directional migration in vitro, and possibly acts as a trophic
factor in vivo.12,13 HGF plays an important role in tissue repair.
During regeneration, expression of HGF from the damaged
tissue is upregulated, and is highest at 48 h.14,15 The role of
HGF in repair has been well documented in the liver,16,17
heart,18,19 and muscle.20
An HGF receptor c-Met is expressed on hematopoietic
progenitors that respond to HGF21–29 as well as cells that are
capable of regenerating liver and muscle. c-Met is expressed
on immature human marrow-derived hematopoietic stem/
progenitor cells with the phenotype CD34þCD33 and
CD34þCD38, but not on more mature progenitors with the
phenotype CD34þCD33þ and CD34þCD38þ.28 Recently, it
has been reported that MSC express both HGF and its
receptor c-Met.13 As predicted, HGF acts as a motogenic
stimulus for MSC, increasing their scattering, as shown by the
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scratch test assay, aswell as directionalmigration/chemotaxis
toward an HGF gradient in a transwell assay. Low concen-
trations of HGF demonstrate a mitogenic effect on MSC, en-
hancing their proliferation rate.30 Surprisingly, high levels of
HGF have a negative effect on MSC proliferation in vitro.12,13
In several in vivo injury models, MSC overexpressing HGF
have been shown to improve cardiac tissue regeneration after
myocardial infarction injury faster than nontransduced
MSC,31 whereas HGF knockdown (KD) in MSC rendered
them unable to improve revascularization in the hindlimb
ischemia injurymodel.32 Altogether, these results suggest that
HGF does play a key role in ischemic tissue repair.
The tissues and cells of multicellular organisms have an
ability to sense low oxygen availability, to ensure an adequate
oxygen supply to all tissues. The cellular response to hypoxia
is important for tissue survival, and plays a role in cancer
and other ischemic diseases. For instance, hypoxia activates
multiple proteins that promote the angiogenesis and glu-
cose transport pathways to improve survival in the affected
cells.5,33–37 Hypoxic stimulation has been previously shown to
activate the HGF/c-Met signaling pathway. c-Met, the re-
ceptor for HGF, is rapidly internalized and degraded after
ligand binding.38,39 There is evidence suggesting that hypoxia
enhances not only expression of c-Met but also its protein
stability.40
In our previous studies, we demonstrated that the HGF
receptor c-Met is upregulated in MSC that are cultured at
1%–3% oxygen, whereas these cells are then able to mediate
tissue repair more robustly at an early time point than MSC
cultured at 21% oxygen.5 In the current report, we examine
the effect of c-Met KD on the characteristics, differentiation
potential, and function of human MSC. First, we assessed the
in vitro characteristics of KD MSC, including their cell surface
marker profile, colony-forming efficiency, and differentiation
potential, and then we determined whether HGF/c-Met
signaling is important in the in vivo tissue repair capacity of
MSC in a hindlimb ischemia injury model.
Materials and Methods
Cell culture
MSC were cultured from normal human donor marrow
aspirates, as we have previously described.41,42 All studies
were done in accordance with university regulatory com-
mittees. Aspirates were filtered through 70mm filters (BD
Falcon Ref 352350) and the filters were subsequently flushed
with the MSC medium (Iscove’s Modified dulbecco’s mod-
ified Eagle’s medium [DME], 15% fetal bovine serum, 15%
horse serum, 106 M hydrocortisone, 104 M 2-Mercap-
toethanol, and 2mM L-glutamine), to recover bony spicules,
from which MSC were isolated as described.43 Cultures were
kept under 80% confluence at all times. All experiments were
done with cells passaged 3–9 times.
shRNA transduction
shRNA constructs targeting c-Met and scrambled control
were purchased from Sigma (cat# NM_000245, SHC002).
Lentiviral vectors expressing these constructs were generated
using pHR’8.2deltaR packaging plasmid and pCMV-VSV-G
envelope plasmid at 8:1 ratio and transfected into 293T cells
in the presence of Fugene (Roche Applied Science; cat. no.
04709691001). MSC were treated with viral supernatant and
10 mg/mL protamine sulfate (Sigma; cat. no. P3369) for 4 h,
and after 48 h selected with 1 mg/mL puromycin (Sigma; cat.
no. P7255).
Western blot analysis
c-Met KD was verified for each batch of shRNA vector-
transduced cells using Western blotting. After washing with
cold phosphate-buffered saline (PBS), lysis buffer (1% Triton
100, 150mM NaCl, 50mM HEPES, 1mM Na3VO4, and pro-
tease inhibitor cocktail [Complete Mini; Roche; cat. no.
11836153001]) were directly applied to MSC on tissue culture
plates. Western blotting was performed as previously de-
scribed.44 Protein bands were quantified using Image J soft-
ware (Rasband, WS; Image J, National Institutes of Health,
http://rsb.info.nih.gov/ij/, 1997–2007).
Flow cytometry
Cells that had been released by cell dissociation buffer
(Gibco; cat. no. 13151-014) were phenotyped using monoclo-
nal antibodies and a BD FACScan flow cytometer. Antibodies
for CD34, CD45, CD90, and CD73 were purchased from
BD Pharmingen (cat. nos. 55824, 34796, 555595, and 550257,
respectively) and CD105 was purchased from R&D Systems
(10971A).
Cell cycle assay
Cells were collected and fixed with ice-cold 90% ethanol,
added drop wise while vortexing. The fixation reaction was
allowed to go 1–24 h, while the cells were kept at 48C. Cells
were then collected by centrifugation and resuspended in PBS
containing 0.1% Triton100 and 20mg/mL RNAse and incu-
bated for 30min at 378C. Propidium Iodide at a final con-
centration of 50 mg/mLwas added and cells were analyzed by
flow cytometry.
Cell viability
MSC were harvested and stained with Annexin V and
7AAD according to the manufacturer’s instructions (Apop-
tosis detection kit; BD Biosciences). The cells were analyzed
using a FACScan flow cytometer (Becton Dickinson).
Colony forming units–fibroblast assay
MSC were plated at a density of 52.6 cells/cm2 in six-well
tissue-culture-coated plates in the MSC medium. Fourteen
days after plating the cells were fixed with cold methanol for
5min and stained with Giemsa stain (Sigma; cat. no. GS500).
The number of colonies was counted using a phase-contrast
microscope (Nikon TMS).
Differentiation assays
The differentiation assays were performed according to
manufacturer’s instructions (Lonza). At the end of differen-
tiation process, the cell monolayers were fixed with cold
methanol for 5min and air-dried. The adipogenic cultures
were stained with Oil Red O (Sigma; cat. no. O0625) as pre-
viously described.45 The osteogenic cultures were stained
with Alizarin Red S (Sigma; cat. no. A5533), 2% Alizarin Red
S, pH 4.2 solution for 5min, washedwithwater, and air-dried.
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The chondrogenic pellets were either frozen, cryosectioned,
and stained with Alcian Blue (Rowley Biochemical; cat.
no. E-325) (n¼ 1 pellet per treatment), or fixed in 10% for-
malin, paraffinized, sectioned, and stained with Safranin O.
The pictures were taken with an upright Olympus BX41 mi-
croscope and Olympus DP20 camera (Olympus Imaging
America Inc.), or Nikon Eclipse TE300 inverted microscope
(Nikon) and Magnafire camera model S99802 (Optronics).
Hypoxia
The hypoxic condition was generated using a hypoxia
chamber (Stem Cell Technologies; cat. no. 27310) according to
the manufacturer’s instructions. Briefly, the cultures were
enclosed in the chamber and flushed with a mixture of gasses
(95% N2 and 5% CO2) for 3min. At the end of the flushing
period, the chamber was closed to prevent free flow of exo-
genous air into the chamber. The final level of hypoxia
was 1%–3%, as specified by the manufacturer. The cells were
incubated in hypoxic conditions for 21.5 to 28 h before trans-
plantation.
Animal surgery and MSC injection
All animal procedures were approved by the Animal Stu-
dies Committee at Washington University in St. Louis. Under
anesthesia, NOD/SCID mice were subjected to unilateral
hindlimb ischemia surgeries as described.46,47 The mice were
shaved and prepped; then, the right femoral artery and vein
were exposed and dissected from the femoral nerve; the
proximal portion of the femoral artery and vein was ligated
with 6–0 silk sutures. The distal portion of the saphenous
artery and vein and the remaining collateral arterial and ve-
nous side branches were ligated and completely excised from
the hindlimb. The overlying skin was closed using Nexaband
veterinary glue (Abbott Animal Health). Anti-CD122 anti-
body, to reduce murine NK activity, was injected intraperi-
toneally at a concentration of 200mg/mouse right after the
surgery. MSC (106 cells per mouse) were injected intramus-
cularly into the injured area in 100mL of PBS in three different
sites 1 day after the surgery.
Laser Doppler perfusion imaging
Blood perfusion was monitored by laser Doppler imaging
(MoorLDI-2; Moor Instruments). Animals were anesthetized
and placed on a heating block at 378C before scanning to
minimize temperature variations. The laser Doppler images
were analyzed by averaging the perfusion, expressed as the
relative unit of flux over the surface of both ischemic and
nonischemic foot, as determined by the Doppler imaging. The
final data were expressed as the flux ratio of ischemic and
nonischemic foot. This provides a healthy contralateral posi-
tive control in each image, to minimize light and temperature
variations.
Statistics
One-way analysis of variance (ANOVA) was used to ana-
lyze the statistical significance in all in vitro experiments.
The significance of the in vivo hindlimb ischemia functional
studies was examined using two-way ANOVA analysis. A
p-value <0.05 was considered to be significant throughout
all studies.
Results
shRNA KD of c-Met in MSC
To study the importance of HGF/c-Met signaling for MSC
function, we used shRNA constructs to generate a KD of
c-Met in MSC. Two out of five constructs tested resulted in
60%–70% KD of the protein, as confirmed by Western blot-
ting, whereas the level of c-Met protein in MSC SCR was
unaffected (Fig. 1a). The average KD level of c-Met protein
from multiple transduction experiments was quantified by
densitometry and c-Met semi-quantification was normalized
by tubulin expression. There was no significant difference
in the level of reduction in protein levels between the two
vectors ( p> 0.05, Fig. 1b), whereas both were significantly
decreased as compared to the scrambled control ( p< 0.05,
n¼ 9).
The KD of c-Met in MSC does not alter
expression of phenotypic cell surface markers
In the following experiments, we investigated whether
c-Met KD MSC can maintain their in vitro characteristics.
Although there are no exclusive cell surface markers for
MSC, the previously established minimal criteria require
MSC to express CD73, CD90, and CD105 on their cell sur-
face, as well as to lack CD34 and CD45 markers.1 The flow
cytometry analysis of the KD MSC and the MSC transduced
with scrambled control shRNA (SCR) MSC showed that both
groups of cells did present equivalent levels of the appro-
priate cell surface markers (Fig. 2), suggesting that neither
the process of transduction nor the lack of c-Met signaling
disrupted the cell surface phenotype of the MSC. The aver-
age numbers of cells expressing CD73, 90, and 105 with the
standard deviations are summarized in Table 1.
The KD of c-Met in MSC has no apparent effect
on cell cycle, survival, or colony-forming efficiency
HGF/c-Met signaling has been previously implicated to
have a mitogenic function.10,11 To determine whether c-Met
KD affects MSC proliferation, the cell cycle status of MSCwas
analyzed by flow cytometry. Figure 3a summarizes the data
and shows that there was no difference between KDMSC and
SCR MSC in the percentage of cells in the different phases of
the cell cycle. Additionally, the proportion of cycling cells in
this experiment was similar to that of the nontransduced
MSC, as shown in previous studies.5
We next investigated the effect of c-Met KD on MSC
survival. The results of flow cytometry analyses demonstrate
that there was an equivalent fraction of dead and apoptotic
cells in KD MSC and SCR MSC, suggesting that 62%–70%
KD of c-Met did not alter the viability of MSC (Fig. 3b).
To further characterize KD MSC in vitro, we examined
their colony-forming efficiency, which is a measure of the
proliferative potential of the MSC. The colony forming unit–
fibroblast (CFU-F) assay has been shown to be predictive of
differentiation potential, as well as to indicate the self-renewal
capacity of theMSC.48 Data analyzed using one-wayANOVA
and the Bonferroni postanalysis showed significant differ-
ences in untransduced versus scrambled ( p< 0.05) and un-
transduced versus 4246 MSC ( p< 0.05) (Fig. 3c). Altogether,
these data suggest that transduction by shRNA vectors did
cause a reduction in CFU-F formation, but that, as compared
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to the scrambled control, interference with c-Met did not
significantly affect the proliferative capacity of MSC.
HGF/c-Met signaling is required for osteogenic
and chondrogenic, but not adipogenic, differentiation
of MSC
An important indicator of the stem cell potential of MSC is
their capacity to differentiate in vitro into multiple lineages.
We next tested the ability of KD MSC to differentiate into the
adipogenic, osteogenic, and chondrogenic lineages. Notably,
SCR MSC demonstrated a differentiation potential that was
equivalent to unmaninpulated MSC in all three differentia-
tion pathways (Fig. 4). Further, Oil red O staining revealed
that KD MSC could differentiate into adipocytes to the same
degree as SCR MSC, indicating that HGF/c-Met signaling
is not necessary for this differentiation pathway (Fig. 4a). The
osteogenic and chondrogenic differentiation, however, was
decreased in KD MSC as compared to SCR MSC (Fig. 4b, c).
Notably, 4571 shRNA construct, which resulted in 60% c-Met
KD in MSC, exhibited an intermediate phenotype in both
chondrogenic and osteogenic differentiation assays, as
4571KD MSC could produce a low level of glycosaminogly-
can staining and calcium deposits, respectively. The 4246
FIG. 1. Western blot analysis of shRNA-mediated c-Met KD. (a) MSC were transduced with lentivirus expressing shRNA
constructs targeting HGF-receptor c-Met or scrambled control. The level of c-Met KD was assessed after the puromycin
selection usingWestern blot analysis. Both vectors 4246 and 4571 resulted in observable KD, whereas the scrambled control did
not affect the c-Met protein levels on MSC. (b) The KD of c-Met was verified after every transduction, and the level of KD was
semi-quantitated using densitometry analysis (Image J). C-Met semi-quantification was normalized by tubulin expression.
Therewas no significant difference in the level of reduction in protein levels between the two vectors ( p> 0.05), while bothwere
significantly decreased as compared to the scrambled control ( p< 0.05). The data are representative of nine transductions of
primary MSC with the scrambled, 4246, and 4571 vectors. MSC, mesenchymal stem cells/marrow stromal cells; HGF, hepa-
tocyte growth factor; KD, knockdown; BMSC, bone-marrow-derived MSC.
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FIG. 2. Marker profile of KD MSC. The cell surface marker profile of KD versus scrambled shRNA MSC (KD MSC and SCR
MSC, respectively) was analyzed using flow cytometry analysis. There was no difference between KD MSC and SCR MSC in
their cell surface marker expression. Consistent with MSC characteristics, MSC lacked hematopoietic markers CD34 and
CD45 (a) and expressed MSC markers CD105 and CD90 (b) and CD73 (c). The gates were set based on the analysis of cells
stained with IgG controls, as shown in (d), (e), and (f), respectively. The images are representative of three separate ex-
periments. The summary of the flow cytometry data (% of cells expressing the marker standard deviation) is shown in
Table 1. SCR, scrambled control shRNA.
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shRNA construct, which resulted in 70% c-Met KD in MSC,
caused a more pronounced reduction in both chondrogenic
and osteogenic differentiation of MSC. In addition to the lack
of Safranin O staining, the chondrogenic pellets from 4246
MSC were also smaller in size and in general comparable to
the pellet of MSC that had not been stimulated with chon-
drogenic differentiation factors (Fig. 4c). Interestingly, this
result is consistent with the colony-forming efficiency of MSC
transduced with this clone, as well as with the level of c-Met
protein KD, which was higher for this construct. Nonetheless,
Table 1. Summary of Marker Profile of Knockdown Mesenchymal Stem Cells/Marrow Stromal Cells
CD90 CD73 CD105
c-Met KD (4246) 95.06 3.5 78.35 18.37 92.31 1.95
c-Met KD (4571) 88.25 6.9 90.39 2.91 98.5 1.97
Scrambled control 82.43 14.47 84.44 8.03 88.5 7.86
MSC marker cell surface expression was analyzed using flow cytometry, and the data from three separate experiments are summarized
as a percentage of cells that expressed a marker standard deviation.
MSC, mesenchymal stem cells/marrow stromal cells; KD, knockdown.
FIG. 3. c-Met KD does not alter MSC cell cycle, survival, or colony-forming efficiency. (a) Cell cycle: KD MSC or SCR MSC
were permeabilized, stained with propidium iodide and their cell cycle status was assessed based on their DNA content. The
bar graph summarizes the results of three separate experiments, showing that there was no significant difference in prolif-
eration between KD MSC and SCR MSC. (b) Survival: KD or SCR MSC were collected, stained with Annexin V and 7AAD,
and analyzed by flow cytometry. The bar graph summarizes the proportion of dead and apoptotic cells from three separate
experiments, and demonstrates no significant differences. (c) CFU-F assay: MSC were plated at low density (500 cells/well of
six-well plate) and the colonies were counted after 14 days of culture. The bar graph summarizes the data from two separate
experiments (n¼ 6 for each treatment), showing that although there was a significant difference between transduced and
untransduced MSC (*), there was no significant difference between KD MSC and SCR MSC as assessed using one-way
ANOVA. CFU-F, colony forming unit-fibroblast; ANOVA, analysis of variance.
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FIG. 4. HGF/c-Met signaling alters the osteogenic and chondrogenic differentiation capacity ofMSC, but not their adipogenic
differentiation potential. MSC were cultured in the commercial differentiation medium to stimulate differentiation along
adipogenic, osteogenic, and chondrogenic lineages. (a) Adipogenic cultures were stained with Oil Red O, showing no differ-
ences between c-Met KDMSC and SCRMSC in their adipogenic differentiation capacity. (b) Alizarin Red S staining of calcium
deposits revealed a decrease of osteogenic differentiation in KD MSC compared to SCR MSC and untransduced MSC. (c)
Safranin O staining of chondrogenic pellets demonstrated a decrease in chondrogenic differentiation potential in KD MSC
compared to SCR MSC and untransduced MSC. Notably, the level of differentiation of SCR MSC in all three differentiation
assays was comparable to the untransduced MSC. Shown are representative images of 5–7 replicates of osteogenic and
adipogenic cultures performed in three separate experiments. The chondrogenic assays were performed as three independent
replicates.
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FIG. 5. The effect of HGF/c-Met signaling on MSC tissue repair capacity in a hindlimb ischemia injury model. (a) Hindlimb
ischemia surgeries were performed on immunodeficient NOD/SCIDmice, followed by intraperitoneal injection of anti-CD122
antibody. Approximately 24 h after the surgery, the mice were injected intramuscularly with 106 human BMSC that had been
cultured at 3% oxygen or 21% oxygen. The blood flow recovery to the ischemic limb was followed by laser Doppler perfusion
imaging for 2 weeks after the surgery. (b) The laser Doppler perfusion imaging results demonstrate that the mice injected with
hypoxia-preconditionedMSC recovered significantly better than the saline controls (two-way ANOVA), whereas there was no
significant difference between the control group and the group injected withMSC cultured in 21% oxygen (two-way ANOVA).
On the basis of these results, theMSC used in our next hindlimb ischemia experiment were all preconditioned at 1%–3% oxygen
before the transplantation. (c) Mice injected with SCR MSC were able to improve blood flow recovery after hindlimb ischemia
to the same degree as nontransducedMSC; both SCR- and nontransducedMSC restored blood flow significantly faster than the
saline controls (two-way ANOVA). The blood flow recovery in mice transplanted with 4246KD MSC (70% KD of c-Met) was
significantly slower than that in the SCR MSC group (two-way ANOVA). (d) The blood flow recovery of animals treated with
4571KD MSC (60% c-Met KD) was not significantly different from those treated with SCR MSC. The summarized data are
based on seven (b, hypoxic and PBS groups) and eight (b, normoxic) animals per group. The graphs shown in (c) and (d) belong
to the same experiment and are only separated to improve clarity. Therefore, these data can be directly compared to each other,
and the SCRMSC and PBS curves are identical in both graphs. The data are representative of 12 (4246), 14 (untransduced MSC
and SCR MSC), and 15 (PBS and 4571) animals per group. *Signifies p< 0.05 compared with saline-treated mice. NS, not
significant. PBS, phosphate-buffered saline. Color images available online at www.liebertonline.com/ten.
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the fact that both KD vectors did decreaseMSC differentiation
potential suggests that HGF/c-Met signaling is necessary for
both osteogenic and chondrogenic differentiation processes.
MSC-mediated blood flow recovery
after hindlimb ischemia
We next examined whether HGF/c-Met signaling is im-
portant for the tissue repair potential of MSC in vivo, using a
murine xenotransplantation hindlimb ischemia injury model.
In previous studies, we have demonstrated that human bone-
marrow-derived MSC can significantly improve blood
flow recovery in the ischemic hindlimb in NOD/SCID/Beta
2 microglobulin null (B2M/) immunodeficient mice.
Additionally, we have shown that culturing MSC at 1%–3%
oxygen before transplantation resulted in amore robust blood
flow recovery at an early time point.5 In the current experi-
ments, we first investigated whether this finding is repro-
ducible in NOD/SCID mice, which had been injected with
anti CD122 antibody to reduce rejection of human cells, as
previously described.49 Approximately 24 h after the hind-
limb ischemia surgery, animals were injected intramuscularly
with 1 million human bone-marrow-derived MSC that had
been cultured at 1%–3% oxygen or 21% oxygen (Fig. 5a). The
blood flow recovery to the ischemic limb was followed by
Laser Doppler perfusion imaging. The results revealed that
mice injected with hypoxia-preconditioned MSC recovered
significantly better than the saline control group. There was,
however, no significant difference between mice injected
with MSC cultured at 21% oxygen and the saline controls
(Fig. 5b). Therefore, the MSC used in subsequent experiments
were always preconditioned in a hypoxic environment before
injection.
We next assessed the ability of c-Met KD MSC to mediate
blood flow regeneration after a hindlimb ischemia injury.
Using the same experimental design as described above
(Fig. 5a), we showed that SCR MSC had a tissue repair ca-
pacity comparable to that of nontransduced MSC, and that
they significantly improved the regeneration of blood flow to
the ischemic limb compared to the saline control group
(Fig. 5c). Further, the comparison between SCR MSC and KD
MSC revealed that 4246KDMSC,which had c-Met expression
reduced by 70%, were not able to improve regeneration after
the hindlimb ischemia injury, as the mice injected with these
cells recovered significantly more slowly than the SCR MSC
group and to a similar degree as the saline controls. The
4571KD MSC, however, which had less reduction in c-Met
levels, exhibited an intermediate phenotype. Their regenera-
tion ability was not significantly different from that of SCR
MSC (Fig. 5d). These data therefore demonstrate that 60% KD
of c-Met did not cause a significant defect in MSC-mediated
blood flow recovery in the hindlimb ischemia injury model,
whereas 70% KD of c-Met ablated the potential of MSC to
mediate repair in this model.
Discussion
MSC are known to secrete a variety of cytokines and
growth factors that have both paracrine and autocrine activ-
ities. The predominant mechanism of tissue repair and re-
generation by MSC appears to be that they home or lodge in
hypoxic and/or inflamed areas and release factors that hasten
endogenous repair. These secreted bioactive factors suppress
the local immune system, enhance angiogenesis, strengthen
small collateral vessels, inhibit fibrosis and apoptosis, and
stimulate recruitment, retention, mitosis, and differentiation
of endogenous stem cells. These effects, which are referred to
as ‘‘trophic effects,’’ are distinct from the direct differentia-
tion of stem cells into the tissue to be regenerated. It is im-
portant to understand the signaling pathways involved in
stem cell recruitment to hypoxic or damaged regions, to de-
velop improved models for enhancing tissue repair using
adult stem cells.
We have previously reported that pretreatment of MSC
under hypoxic conditions increased the levels and extent of
activation of c-Met,50 which could enhance HGF-mediated
chemotactic recruitment to sites of tissue damage. This could
also enhance the survival ofMSC upon arrival at the damaged
site, through increasing the levels of phosphorylation of the
pro-survival protein AKT. Phosphorylation of Akt on Ser-473,
which we had shown to be enhanced in hypoxic precondi-
tioned MSC,50 stimulates its activity and plays a major role in
the suppression of anoikis,51 or ‘‘death by detachment.’’ This is
especially important for MSC, which begin to undergo apo-
ptosis within hours after their integrin detachment from the
substrate. AKT has been used to modify MSC for injection
to circumvent this problem. Gnecchi et al. showed that, in a
mouse model, a conditioned medium from AKT-transduced
MSC had the same protective effect as the injected cells in
acute myocardial infarction.52 These data, and others, suggest
that a paracrine effect from the MSC is more important
than direct differentiation or fusion. Our previous data
showed that preculture of the cells in hypoxia before injection
naturally increased AKT activity, without artificial over-
expression, which could be tumorigenic.
In the current study, we investigated the importance of
HGF/c-Met signaling in MSC and specifically its influence
on the in vitro and in vivo characteristics of these cells. We
show that two different shRNA vectors were able to KD the
level of c-Met protein in MSC to 30% and 40% of expression
of scrambled control-transduced cells. Further, we show that
this signaling pathway did not affect MSCs’ cell surface
marker profile, their cell cycle progression, or their survival.
Upon examining the differentiation potential of c-Met KD
MSC, we discovered that although KD MSC were able to
differentiate into the adipogenic lineage, the decrease in
HGF/c-Met signaling caused a defect in their chondrogenic
and osteogenic differentiation potential. Although HGF
has been implicated to promote osteogenic differentiation of
MSC,30 to our knowledge this is the first report showing a
defect in MSCs’ osteogenic and chondrogenic differentiation
capacity after a genetic KD of this signaling pathway.
In additional in vivo studies, we next demonstrated that
although 60% KD of c-Met had only an intermediate effect on
the tissue repair capacity of MSC, a 70% KD of this receptor
caused a significant decrease in their ability to promote
blood flow regeneration after a hindlimb ischemia injury.
The 60% KD of c-Met in MSC also displayed an intermediate
phenotype in osteogenic and chondrogenic differentiation
assays, when compared to the 70% KD.
MSCwere initially identified as fibroblast-like cells resident
to the bone marrow, which can form tissue-culture-adherent
colonies in vitro.53 After their ability to reconstitute a bone
marrowmicroenvironment in vivowas discovered,54–56 many
researchers have tried to characterize these cells and their
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in vitro properties. Although no exclusive cell surface marker
for MSC has been identified, a minimal set of markers that
they lack or express has been established.1 Additionally, a
CFU-F assay was established as a measure of MSC colony-
forming efficiency to reflect their self-renewal capacity. In this
study, we show that neither MSC marker profile nor their
colony-forming efficiency is altered after a c-Met KD. As
HGF/c-Met signaling was expected to alter the MSC function
rather than their phenotype, it is not surprising that KD MSC
still express the key characteristic markers. It is, however,
somewhat unexpected that KD MSC colony-forming effi-
ciency is comparable to that of SCR MSC, especially in the
light of the fact that HGF is a known mitogenic factor. A low
concentration of HGF has been previously shown to increase
the MSC proliferation rate,30 while high HGF concentrations
are known to be inhibitory to MSC growth.12,13 We predicted
that MSC production of HGF in addition to that present in the
serum would result in low levels of HGF in the tissue culture
medium, towhich KDMSCwould not be able to respond. The
cell cycle analysis and the CFU-F assay of KDMSC, however,
showed no significant differences when compared to the SCR
MSC, suggesting that 60%–70% KD of c-Met is not sufficient
to alter MSC proliferation and self-renewal. These results are
in contrast to previously published data, which demonstrated
a diminished growth of MSC treated with anti c-Met anti-
body.30 It is, nevertheless, possible that a higher level of c-Met
KD is necessary to see an effect in these assays.
Another important characteristic that defines MSC is their
in vitro differentiation potential. MSC have been shown to be
able to differentiate into multiple lineages, but the three best
defined are adipogenic, chondrogenic, and osteogenic. In this
study, we demonstrate that MSC expressing decreased levels
of c-Met were able to differentiate into adipocytes; however,
these cells exhibited a defect in their osteogenic and chon-
drogenic differentiation. Previous studies have shown that
while HGF supplementation alone did not induce osteogenic
differentiation, HGF in concert with vitamin D3 was able to
induce bone matrix mineralization in culture.30 Our results
confirm the observation that HGF signaling is important for
osteogenic differentiation, demonstrating that the loss of this
signaling pathway leads to a decreased formation of bone
nodules. Additionally, we make a novel observation that
the HGF/c-Met axis is also necessary for chondrogenic dif-
ferentiation, as the KD MSC were not able to produce
extracellular matrix characteristic for cartilage. Although
signaling pathways involved in MSC fate determination are
complicated and are still not well understood, a number of
them such as insulin-like growth factor, fibroblast growth
factor, and transforming growth factor-b have been impli-
cated to be involved in processes leading to both chon-
drogenesis and osteogenesis.57,58 Our results prompt further
investigation into the possibility that HGF/c-Met signaling
interacts with some of these pathways, which could explain
why disrupted signaling along this axis does not affect the
adipogenic differentiation, but plays a significant role in os-
teogenic and chondrogenic differentiation.
The major interest in MSC research has been due to their
tissue repair potential. Our group and others have previously
demonstrated that MSC are able to mediate blood flow re-
generation in the hindlimb ischemia injury model.5,7,59,60 In
this report, we show that a 70% KD of the c-Met receptor
on MSC disrupted their capacity to improve recovery after an
ischemic injury, whereas a 60% KD of c-Met exhibited an in-
termediate effect, not statistically significant from the blood
flow recovery stimulated by SCR MSC. HGF has been pre-
viously implicated to be effective in improving blood flow in
several animal models of angiogenesis as well as in clinical
trials.5,61–63 In a myocardial infarction injury model, MSC
overexpressing HGF have been shown to improve cardiac
tissue regeneration faster than nontransduced MSC, sug-
gesting that HGF does play a key role in ischemic tissue re-
pair.31 Additionally, multiple in vitro studies revealed that
MSC support endothelial cell survival, proliferation, and tube
formation, and that this in vitro effect is dependent on the
release of endogenous HGF and vascular endothelial growth
factor.59 In agreement with these results, HGF KD in MSC
rendered the cells unable to improve blood flow in the hin-
dlimb ischemia injury model.32 Altogether, these results
suggest that HGF is an important growth factor that signifi-
cantly contributes to ischemic injury regeneration, and that
the ability of MSC to mediate tissue repair is partially due to
their release of this cytokine. The data presented in the current
study confirm the importance of HGF/c-Met signaling for the
ability of MSC to mediate tissue repair. Our data further
suggest that not only does HGF act as a trophic factor on the
endogenous cells in the injury area, but also the c-Met sig-
naling is necessary for the MSC to respond properly to the
injury signals and thus to mediate blood flow recovery in
ischemic tissues. In our study the 60% KD of c-Met did not
recapitulate the phenotype of the 70% c-Met KD. Several lines
of evidence suggest that the level of c-Met expression is im-
portant. The 60% KD cells have, for example, showed an in-
termediate phenotype in the chondrogenic and osteogenic
differentiation assays, as well as significantly higher colony-
forming efficiency than the 70% KD MSC. This suggests that
MSC are sensitive to local gradients and microenvironmental
bioavailability of HGF to activate c-Met, like many growth
factor/receptor pairs.
In this report, we have uncovered the importance of the
HGF/c-Met signaling pathway in the osteogenic and chon-
drogenic potential of human MSC, as well as in their capacity
for tissue repair. We assessed the capacity of MSC with c-Met
reduced to variable levels by shRNA to produce bone min-
eralized nodules and cartilage-specific extracellular matrix
as endpoints to test their osteogenic and chondrogenic dif-
ferentiation, respectively. In future studies, it would be in-
teresting to investigate whether these MSC are arrested at a
particular stage of differentiation, and whether HGF/c-Met
signaling interacts with other signaling pathways that regu-
late chondrogenic and osteogenic cell determination. We also
determined the importance of c-Met signaling in the capacity
of human MSC to increase blood flow in a hindlimb ischemia
model. The understanding of how MSC mediate tissue repair
and whether the c-Met KD affects their cytokine secretory
profile would be an intriguing future direction that could
contribute to improving the clinical treatment of ischemic
diseases.
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